Global Behavioural Health Treatment Market is expected to witness a CAGR of 2.9% during the forecast period of 2022 to 2032 | Fact.MR Report
21 mars 2023 10h00 HE
|
FACT.MR
Rockville, March 21, 2023 (GLOBE NEWSWIRE) -- The market for Behavioural Health Treatments will expand at a CAGR of 2.9%, over the forecasted time. The rise of telepsychiatry procedures in the...
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
08 mars 2023 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
01 mars 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Global Psychiatrists Market Report 2022: Rising Government Support for Mental Health Reforms is Expected to Propel Growth
30 déc. 2022 06h28 HE
|
Research and Markets
Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "Psychiatrists Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
28 déc. 2022 08h00 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Olanzapine Market Is Expected to Reach USD 2.2 Billion by 2031, Says Allied Market Research
01 déc. 2022 04h56 HE
|
Allied Market Research
Portland, OR, Dec. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global olanzapine market generated $1.8 billion in 2021, and is estimated to reach...
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
09 nov. 2022 08h00 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
22 août 2022 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
09 août 2022 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
When Medicine is Not Enough for Schizophrenia and Psychosis
30 juin 2022 09h00 HE
|
Brain & Behavior Research Foundation
New York, June 30, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “When Medicine is Not Enough for Schizophrenia and Psychosis” on Tuesday,...